Treatment of perianal fistulas with human embryonic stem cell-derived MSCs: a canine model of human fistulizing Crohn's disease
Open access Research Article by Robert Lanza, Andrew Hoffman et al. presenting that canine models of refractory Crohn’s disease that receive a hESC-derived mesenchymal cell therapy undergo remission
Crohn's disease is a chronic inflammatory condition affecting millions. Current treatments are not always effective and patients often become refractory, leaving the patients in dire need of a new therapy. Canine anal furunculosis shares many features with Crohn’s disease and dogs have a physiology and immune system closely resembling humans, making them a good animal model for this condition.
Lluís Ferrer, Erin A Kimbrel, Andrea Lam, Elizabeth B Falk, Christine Zewe, Tarja Juopperi, Robert Lanza and Andrew Hoffman from Tufts Cummings School of Veterinary Medicine and Ocata Therapeutics (both MA, USA) have published an open access Research Article titled 'Treatment of perianal fistulas with human embryonic stem cell-derived MSCs: a canine model of human fistulizing Crohn's disease' demonstrating for the first time the safety and therapeutic potential of hESC-MSCs in a large animal model of human fistulizing Crohn’s disease.
Read the full, open access article here.